36 patents
Utility
Delayed Release Compositions of Linaclotide
14 Dec 23
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Angelika Fretzen, Mark G. Currie, Ahmad Hashash, Mahendra Dedhiya, Yun Mo, Anil Chhettry, Matthew Miller, Ritesh Sanghvi, Mohammad Mafruhul Bari, Andreas Grill
Filed: 28 Aug 23
Utility
Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
2 Nov 23
The invention provides methods for treating a patient with a disorder, such as a GI disorder or symptoms associated with a GI or non-GI disorder, by administering a therapeutically effective amount of a delayed release pharmaceutical composition comprising linaclotide.
Wilmin Bartolini
Filed: 13 Jul 23
Utility
Stable Formulations of Linaclotide
2 Nov 23
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
Filed: 7 Jul 23
Utility
Treatments for Gastrointestinal Disorders
26 Oct 23
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Angelika Fretzen, Hong Zhao, Marco Kessler
Filed: 16 Jun 23
Utility
Treatments for Gastrointestinal Disorders
31 Aug 23
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
Filed: 5 May 23
Utility
Methods of Treating Upper Gastrointestinal Disorders In Ppi Refractory Gerd
10 Aug 23
Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD.
Bernard Joseph Lavins, Mark G. Currie
Filed: 14 Apr 23
Utility
Delayed Release Compositions of Linaclotide
11 May 23
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Angelika Fretzen, Mark G. Currie, Ahmad Hashash, Mahendra Dedhiya, Yun Mo, Anil Chhettry, Matthew Miller, Ritesh Sanghvi, Mohammad Mafruhul Bari, Andreas Grill
Filed: 30 Dec 22
Utility
Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant
24 Nov 22
Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat.
Vasu SETHURAMAN, David Bruce HEDDEN, Kristen Marie LESKOW
Filed: 5 Aug 22
Utility
Stable Formulations of Linaclotide
28 Jul 22
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
Filed: 14 Apr 22
Utility
Treatments for Gastrointestinal Disorders
21 Jul 22
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Angelika Fretzen, Hong Zhao, Marco Kessler
Filed: 8 Apr 22
Utility
Modified or Targeted Release Formulations of Linaclotide
30 Jun 22
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Ahmad Hashash
Filed: 11 Mar 22
Utility
Methods of Treating Upper Gastrointestinal Disorders In Ppi Refractory Gerd
5 May 22
Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD.
Bernard Joseph Lavins, Mark G. Currie
Filed: 13 Jan 22
Utility
Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
28 Apr 22
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations.
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
Filed: 7 Jan 22
Utility
Treatments for Gastrointestinal Disorders
21 Apr 22
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
Filed: 30 Dec 21
Utility
Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant
14 Apr 22
Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat.
Vasu Sethuraman, David Bruce HEDDEN, Kristen Marie LESKOW
Filed: 20 Dec 21
Utility
Treatment of Constipation-Predominant Irritable Bowel Syndrome
14 Apr 22
The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.
Jeffrey Johnston, Bernard Joseph Lavins, Harvey Schneier
Filed: 20 Dec 21
Utility
Low-Dose Stable Formulations of Linaclotide
3 Feb 22
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Caroline Kurtz
Filed: 18 Oct 21
Utility
Treatments for Gastrointestinal Disorders
16 Dec 21
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Angelika Fretzen, Hong Zhao, Marco Kessler
Filed: 27 Aug 21
Utility
Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
23 Sep 21
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations.
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
Filed: 2 Jun 21
Utility
Methods of Treating Upper Gastrointestinal Disorders In Ppi Refractory Gerd
23 Sep 21
Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD.
Bernard Joseph Lavins, Mark G. Currie
Filed: 2 Jun 21